AI Biology Models Demand Real-World Data, Not Just Code

AI models have churned out impressive results in language and vision. Biology, though, is another beast. Predicting the effects of a new drug or simulating a cell’s behavior demands more than scanning research papers or public datasets. Success hinges on gritty, granular data: clinical trial outcomes, manufacturing logs, and safety reports—details often locked away as trade secrets.

The best public datasets only skim the surface. For medical AI to reach clinical usefulness, it needs access to the kind of technical and proprietary information that rarely leaves the headquarters of pharmaceutical giants or biotech startups. Without such context-rich data, even state-of-the-art algorithms falter when faced with real-world biological messiness.

Recently, experts have started eyeing a surprising source: the data left behind by failed biotech companies. When a biotech startup goes bankrupt, mountains of regulatory filings, drug development records, and experimental data often wind up languishing in legal limbo. These files contain granular information—how a drug was manufactured, where processes broke down, and what safety issues tripped up the trials.

Instead of letting this information disappear, some propose acquiring it through bankruptcy proceedings. The idea is simple but bold: treat data as a salvageable asset, as valuable as lab equipment. The process involves bidding at auctions to secure access to these confidential troves, with the aim of building better training datasets for AI systems.

OpenAI and similar organizations aren’t waiting for public policy to catch up. They’re actively spending to acquire or create proprietary datasets that shed light on the quirks of biology. The logic is clear: every new dataset—even one derived from failed experiments—teaches AI models the limits of what works and what doesn’t. This reduces the risk of AI-generated hallucinations or dangerous blind spots in biomedical applications.

OpenAI’s willingness to pay for these data sources signals a shift: the next breakthroughs in AI biology won’t just emerge from better algorithms, but from richer, previously inaccessible training data. The cost of acquiring these files is dwarfed by the potential benefit—better predictions, safer therapies, and more reliable automation in labs and clinics.

For biotech companies, this trend represents both an opportunity and a challenge. On one hand, the data they once considered a sunk cost could fetch value in the event of a wind-down. On the other, firms may need to rethink how they protect proprietary knowledge. Selling data through bankruptcy could become a new norm, but it also raises questions about data privacy and competitive advantage.

For AI developers, access to these datasets could accelerate product development cycles, reduce regulatory risk, and offer new revenue channels—if they can navigate the legal and ethical hurdles. In the projects we run, we’ve seen firsthand how richer training data can move a model from mere novelty to true clinical impact. The companies that secure access to these information goldmines are poised to set the pace in medical AI.

As this data market takes shape, businesses need to pay attention to due diligence. Not all data is created equal; regulatory context, provenance, and completeness matter. Legal frameworks around ownership, consent, and reuse are still developing. Any company betting on AI for drug discovery or diagnostics should actively evaluate the sources and stewardship of their training data.

The emergence of this market also hints at new business models. Firms specializing in data acquisition, curation, and resale could rise alongside traditional biotech and AI outfits. For now, one thing is clear: in medical AI, superior data—not just smarter code—will separate the leaders from the rest.